Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 286

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Open access
Earl, Helena M, Hiller, Louise, Vallier, Anne-Laure, Loi, Shrushma, McAdam, Karen, Hughes-Davies, Luke, Harnett, Adrian N, Ah-See, Mei-Lin, Simcock, Richard, Rea, Daniel, Raj, Sanjay, Woodings, Pamela, Harries, Mark, Howe, Donna, Raynes, Kerry, Higgins, Helen B, Wilcox, Maggie, Plummer, Chris, Mansi, Janine, Gounaris, Ioannis, Mahler–Araujo, Betania, Provenzano, Elena, Chhabra, Anita, Abraham, Jean E, Caldas, Carlos, Hall, Peter S, McCabe, Christopher, Hulme, Claire, Miles, David, Wardley, Andrew M, Cameron, David A, Dunn, Janet A, Agarwal, Roshan, Algurafi, Hafiz, Allerton, Rozenn, Archer, Caroline, Armstrong, Anne, Bale, Catherine, Barraclough, Lisa, Barthakur, Urmila, Bedi, Carolyn, Benstead, Kim, Bloomfield, David, Bowen, Rebecca, Bradley, Chris, Brown, Jane, Butt, Mohammad, Churn, Mark, Cleator, Susan, Cliff, Joanne, Crellin, Perric, Daly, Margaret, De Silva-Minor, Shiroma, Dhadda, Amandeep, Din, Omar, Down, Sue, Earl, Helena, Eaton, David, Eichholz, Andrew, Epurescu, Daniel, Goh, Chee, Goodman, Andrew, Grieve, Robert, Hadaki, Maher, Harper-Wynne, Catherine, Harries, Mark, Hayward, Larry, Humphreys, Alison, Innes, Helen, Jafri, Mariam, Jegannathen, Apurna, Kelleher, Muireann, Kristeleit, Hartmut, Lee, Daniela, Lupton, Susan, MacGregor, Carol, Malik, Zafar, Mansi, Janine, Marshall, Jennifer, McAdam, Karen, McGolick, Trevor, Mehra, Rakesh, Miles, David, Mithal, Natasha, Moss, Charlotte, Moss, Aian, Mukesh, Mukesh, Neal, Anthony, Nelmes, Daniel, Neville-Webbe, Helen, Newby, Jacqueline, O'Reilly, Susan, Ostler, Peter, Persic, Mojca, Pettit, Laura, Raj, Sanjay, Raja, Fharat, Rea, Daniel, Reed, Catherine, Rigg, Anne, Roe, Helen, Shah, Nihal, Simmonds, Peter, Sims, Eliot, Smith, Sarah, Storey, Nicola, Taylor, Wendy, Thanvi, Narottam, Tipples, Karen, Vaidya, Jayant, Varughese, Mohini, Vinayan, Anup, Walji, Nawaz, Waters, Simon, Woodings, Pamela, Wright, Kathryn, Yahya, Sundus · 2019 · The Lancet

Abstract

BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non-inferior to the standard 12-month treatment regarding disease-free survival. METHODS: This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in the UK. We randomly assigned patients with HER2-positive early breast cancer, aged 18 years or older, and with a clear indication for chemotherapy, by a computerised minimisation process (1:1), to receive either 6-month or 12-month trastuzumab delivered every 3 weeks intravenously (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg) or subcutaneously (600 mg), given in combination with chemotherapy (concurrently or sequentially). The primary endpoint was disease-free survival, analysed by intention to treat, with a non-inferiority margin of 3% for 4-year disease-free survival. Safety was analysed in all patients who received trastuzumab. This trial is registered with EudraCT (number 2006-007018-39), ISRCTN (number 52968807), and ClinicalTrials.gov (number NCT00712140). FINDINGS: Between Oct 4, 2007, and July 31, 2015, 2045 patients were assigned to 12-month trastuzumab treatment and 2044 to 6-month treatment (one patient was excluded because they were double randomised). Median follow-up was 5·4 years (IQR 3·6-6·7) for both treatment groups, during which a disease-free survival event occurred in 265 (13%) of 2043 patients in the 6-month group and 247 (12%) of 2045 patients in the 12-month group. 4-year disease-free survival was 89·4% (95% CI 87·9-90·7) in the 6-month group and 89·8% (88·3-91·1) in the 12-month group (hazard ratio 1·07 [90% CI 0·93-1·24], non-inferiority p=0·011), showing non-inferiority of the 6-month treatment. 6-month trastuzumab treatment resulted in fewer patients reporting severe adverse events (373 [19%] of 1939 patients vs 459 [24%] of 1894 patients, p=0·0002) or stopping early because of cardiotoxicity (61 [3%] of 1939 patients vs 146 [8%] of 1894 patients, p<0·0001). INTERPRETATION: We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events. These results support consideration of reduced duration trastuzumab for women at similar risk of recurrence as to those included in the trial. FUNDING: UK National Institute for Health Research, Health Technology Assessment Programme.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)30650-6

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 286

Metadata

Authors
Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., McAdam, K., Hughes-Davies, L., Harnett, A. N., Ah-See, M.-L., Simcock, R., Rea, D., Raj, S., Woodings, P., Harries, M., Howe, D., Raynes, K., Higgins, H. B., Wilcox, M., Plummer, C., Mansi, J., Gounaris, I., Mahler–Araujo, B., Provenzano, E., Chhabra, A., Abraham, J. E., Caldas, C., Hall, P. S., McCabe, C., Hulme, C., Miles, D., Wardley, A. M., Cameron, D. A., Dunn, J. A., Agarwal, R., Algurafi, H., Allerton, R., Archer, C., Armstrong, A., Bale, C., Barraclough, L., Barthakur, U., Bedi, C., Benstead, K., Bloomfield, D., Bowen, R., Bradley, C., Brown, J., Butt, M., Churn, M., Cleator, S., Cliff, J., Crellin, P., Daly, M., De Silva-Minor, S., Dhadda, A., Din, O., Down, S., Earl, H., Eaton, D., Eichholz, A., Epurescu, D., Goh, C., Goodman, A., Grieve, R., Hadaki, M., Harper-Wynne, C., Harries, M., Hayward, L., Humphreys, A., Innes, H., Jafri, M., Jegannathen, A., Kelleher, M., Kristeleit, H., Lee, D., Lupton, S., MacGregor, C., Malik, Z., Mansi, J., Marshall, J., McAdam, K., McGolick, T., Mehra, R., Miles, D., Mithal, N., Moss, C., Moss, A., Mukesh, M., Neal, A., Nelmes, D., Neville-Webbe, H., Newby, J., O'Reilly, S., Ostler, P., Persic, M., Pettit, L., Raj, S., Raja, F., Rea, D., Reed, C., Rigg, A., Roe, H., Shah, N., Simmonds, P., Sims, E., Smith, S., Storey, N., Taylor, W., Thanvi, N., Tipples, K., Vaidya, J., Varughese, M., Vinayan, A., Walji, N., Waters, S., Woodings, P., Wright, K., & Yahya, S.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-06
Volume
393
Issue
10191
Pages
2599-2612
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2948726637
Cited by
286
References
34
FWCI
16.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. https://app.cochat.ai/papers/10.1016/s0140-6736(19)30650-6
The paper
Earl, H. M., Hiller, L., Vallier, A.-L., Loi, S., McAdam, K., Hughes-Davies, L., Harnett, A. N., Ah-See, M.-L., Simcock, R., Rea, D., Raj, S., Woodings, P., Harries, M., Howe, D., Raynes, K., Higgins, H. B., Wilcox, M., Plummer, C., Mansi, J., . . . Yahya, S. (2019). 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. The Lancet. https://doi.org/10.1016/s0140-6736(19)30650-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.